Nascent Biotech founder Dr. Mark C. Glassy has co-authored a new paper appearing in Human Antibodies entitled, “Antibody drug conjugates: Progress, pitfalls,
and promises.”
Vero Beach, FL December 10, 2018 – Nascent Biotech, Inc. (OTC: NBIO) Received US Food and Drug Administration (FDA) Clearance to begin Phase 1 Clinical Trials effective December 7th, 2018.
Nascent CEO Sean Carrick stated, “On Friday December 7, 2018, Nascent Biotech received a letter from the FDA moving the Company’s IND filing from Full Clinical Hold to Partial Clinical Hold, which frees the Company to immediately begin Phase 1 Human Clinical Trials with its present drug lot.” “There are additional product testing criteria required by the FDA, which we believe are very achievable and have already begun to respond,” stated Executive Vice President Dr. Brandon Price.
Nascent founder, Dr. Mark Glassy, commented, “It is gratifying that the FDA will allow Nascent to test the value of Pritumumab in the treatment of advanced brain cancer – a disease with few treatment options and very poor outcomes.”
About Nascent Biotech, Inc.:
Nascent Biotech, Inc is a clinical-stage biotech company engaged in the development of monoclonal antibodies to be used in the treatment of various cancers with an Investigational New Drug (IND) application cleared by the FDA for Phase 1 clinical trials. Its products are not commercially available. For further information please visit our website www.nascentbiotech.com.
Safe Harbor:
Statements in this press release about our future expectations constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc’s ability to target the medical professionals; Nascent Biotech Inc’s ability to raise capital; as well as other risks. Additional information about these and other factors may be described in the Nascent Biotech Inc’s Form 10, filed on October 28, 2014, and subsequent filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
Contact Information:
Nascent Biotech, Inc.
Sean Carrick
President |CEO
772.713.0541
sean.carrick@nascentbiotech.com
www.nascentbiotech.com
The British Journal of Cancer Research has just released a new paper co-authored by Nascent Biotech founder Dr. Mark C. Glassy entitled, “Prionogenicity of vimentin surmised from the sequelog of anti-idiotypic antibodies toward the paratope of malignant associatedautologous anti-vimentin antibody, CLN-IgG (Pritumumab)”.
This October 22-24, 2018, in Riga, Latvia, Human Antibodies & Hybridomas Magazine will present its annual conference. Nascent Biotech will be one of the event’s primary sponsors, with Nascent Biotech founder Dr. Mark Glassy serving as the program chairman.
Click this link to download a PDF detailing the conference details, and how to register.
The Economist has published a fascinating overview of cancer research’s progress, including immunotherapy:
The greatest excitement is reserved for immunotherapy, a new approach that has emerged in the past few years. The human immune system is equipped with a set of brakes that cancer cells are able to activate; the first immunotherapy treatment in effect disables the brakes, enabling white blood cells to attack the tumours. It is early days, but in a small subset of patients this mechanism has produced long-term remissions that are tantamount to cures. Well over 1,000 clinical trials of such treatments are under way, targeting a wide range of different cancers. It is even now possible to reprogram immune cells to fight cancer better by editing their genomes; the first such gene therapy was approved for use in America last month.
Vero Beach FL, August 10, 2016 – Nascent Biotech, Inc., (“Nascent” or “the Company”) (BB: NBIO) is pleased to announce that through the non-dilutive funding recently received, it has paid nearly $1.7 million in payables and debt, plus created positive shareholders equity.
“With this funding we are now able to advance our asset through accelerated filing of our IND by the end of the year,” said Company CFO Lowell Holden. He further stated, “We have now retired all corporate long-term debt and are in a much better position to not only initiate human clinical trials for Pritumumab, a proprietary monoclonal antibody treatment for brain cancer, but also to ultimately expand from brain cancer into other un-met needs in cancer treatment.”
About Nascent Biotech Inc.:
NBI is a biotechnology company developing human Monoclonal Antibodies (mAb’s) for immunotherapy of cancer. Its lead therapeutic candidate, Pritumumab, was the first human antibody ever developed to treat a cancer patient. The company is now developing a new clinical protocol and Initial New Drug (IND) package for commencement of new clinical trials to be conducted in the United States under the guidance of the US Food and Drug Administration (FDA).
Safe Harbor:
This news release contains “forward-looking statements” as that term is defined in the United States Securities Act of 1933, as amended and the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements, including beliefs, plans, expectations or intentions regarding the future, and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors, such as the inherent uncertainties associated with new business opportunities and development stage companies. We assume no obligation to update the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that they will prove to be accurate.
Contact:
Nascent Biotech Inc
Lowell Holden, CFO
Phone: (612) 961-5656
Fax: (612) 486-7055
Email: lowell.holden@nascentbiotech.com
Development planned for multiple Epithelial Cancer Types, starting with brain cancer, in Mainland China.
July 18, 2016 10:00 am EDT
Dateline: TAIZHOU, Zhejiang Province, China & Vero Beach, FL, USA
Public Company Information: OTC: NBIO
Taizhou, Zhejiang Province, China & Vero Beach, FL USA.- Nascent Biotech, Inc. (OTC: NBIO), and Zhejiang Hisun Pharmaceutical Company Ltd., today announced they have entered into an exclusive licensing agreement for the development and commercialization of Nascent’s primary asset, Pritumumab, a monoclonal antibody for the treatment of epithelial cancers (which include brain, pancreas, colon, lung and breast), in mainland China. The agreement between the two companies licenses development, manufacture and commercialization rights for Pritumumab to Hisun, for the treatment of epithelial cancers in China.
“There are significant unmet medical needs in a variety of cancers,” said Sean Carrick, President of Nascent Biotech. “Nascent is committed to changing patient expectations in some of the world’s most debilitating cancers, and licensing Pritumumab to Hisun for therapeutic use in China will bring this promising treatment to significantly more patients who are in need. We’re highly encouraged by the potential of Pritumumab to deliver an innovative, first-in-class treatment option, and we are delighted to be working closely with Hisun in this collaboration.”
Mr. Bai Hua, Chairman of Hisun, expressed that licensing this promising biotech asset will enable Hisun to significantly move forward its goal of diversifying its product portfolio with branded and generic products and achieving Hisun’s long-term vision of “becoming a widely respected international pharmaceutical company” by “persisting in pharmaceutical innovation for the benefit of human beings.”
Under the terms of the agreement, Nascent Biotech will provide to Hisun its Master Cell Bank and related technology, which will allow Hisun to quickly begin manufacturing and further clinical development of Pritumumab in China.
“We are confident that this license agreement will allow Hisun to rapidly fill an unmet need in the cancer space while enabling Nascent to continue to advance this valuable asset in the US. Both companies will benefit greatly from this License arrangement,” added Dr. Haibin Wang, Senior Vice President, Head of Hisun Biopharmaceutical.
About Zhejiang Hisun Pharmaceuticals
With Revenues over $2 Billion annually, Hisun was founded in 1956, the vision of Zhejiang HISUN Pharmaceuticals Co., Ltd. (stock code 600267 – hereinafter called “HISUN”) is to become “a widely respected international pharmaceutical company” by advancing its mission of “persisting in pharmaceutical innovation for the benefit of human beings.” It focuses on the integration of pharmaceutical research and development (R&D) with production resources in order to provide its global customers with outstanding products and services. Visit http://www.hisunpharm.com/.
About Nascent Biotech Inc
Nascent Biotech, Inc is a clinical-stage biotech company engaged in the development of monoclonal antibodies to be used in the treatment of various cancers. Its products are not commercially available. For further information please visit our website www.nascentbiotech.com.
Safe Harbor:
Statements in this press release about our future expectations constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc’s ability to target the medical professionals; Nascent Biotech Inc’s ability to raise capital; as well as other risks. Additional information about these and other factors may be described in the Nascent Biotech Inc’s Form 10, filed on May 2, 2015, and future subsequent filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
Vero Beach, April 25th, 2016 – Nascent Biotech, Inc., (OTC.NBIO) is pleased to announce that it has been granted Orphan Drug Designation from the Office of Orphan Products Development of the FDA for its Pritumumab product for the treatment of Pancreatic cancer. According to Industry statistics, there are approximately 49,000 new cases of Pancreatic Cancer in the United States, annually, with a five year survival rate of 7% and few viable treatment options. This is the second Orphan Drug Designation Granted to Nascent Biotech from the FDA, the first being for use in Primary Brain Cancer.
Dr. Mark Glassy, Nascent Biotech’s founder and Advisory Board Chairman stated, “”It is very satisfying that the FDA has acknowledged the power and importance of Pritumumab in its broad effectiveness in cancer, especially in the un-met need of pancreatic cancer.” He further stated that “We hope to continue to identify additional Orphan Drug Cancers for which Pritumumab will have a significant therapeutic benefit.”
About Nascent Biotech, Inc.:
Nascent Biotech, Inc is a clinical-stage biotech company engaged in the development of monoclonal antibodies to be used in the treatment of various cancers. Its products are not commercially available. For further information please visit our website www.nascentbiotech.com.
Safe Harbor:
Statements in this press release about our future expectations constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc’s ability to target the medical professionals; Nascent Biotech Inc’s ability to raise capital; as well as other risks. Additional information about these and other factors may be described in the Nascent Biotech Inc’s Form 10, filed on May 2, 2015, and future subsequent filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
Contact Information:
Nascent Biotech, Inc.
Sean Carrick
President | CEO
601 21st Street Suite 300
Vero Beach, FL 32960
772.713.0541
sean.carrick@nascentbiotech.com
www.nascentbiotech.com
Vero Beach, FL April 14, 2016 – Nascent Biotech, Inc. (“Nascent Biotech, Inc.” or “the Company”) (OTC.NBIO), announced today that Doug Karas, Vice President of Performance Analysis & Investment Risk at Franklin Templeton Investments, has joined its Board of Directors.
Mr. Karas is a Certified Public Accountant and has extensive accounting, auditing, finance and consulting experience. He will lend similar guidance while serving on Nascent Biotech’s BOD.
Nascent CEO, Sean Carrick, enthusiastically welcomed Mr. Karas and stated that “Mr. Karas will add to the leadership and direction of the Company as we move forward toward our goal of the Company being listed on an exchange at a future date.”
About Nascent Biotech, Inc.:
Nascent Biotech, Inc is a clinical-stage biotech company engaged in the development of monoclonal antibodies to be used in the treatment of various cancers. Its products are not commercially available. For further information, please visit our website: www.nascentbiotech.com.
Safe Harbor:
Statements in this press release about our future expectations constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc’s ability to target the medical professionals; Nascent Biotech Inc’s ability to raise capital; as well as other risks. Additional information about these and other factors may be described in the Nascent Biotech Inc’s Form 10-K, filed on May 2, 2015, and subsequent and future filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
Contact Information:
Nascent Biotech, Inc.
Sean Carrick
President | CEO
601 21st Street Suite 300
Vero Beach, FL 32960
772.713.0541
sean.carrick@nascentbiotech.com
www.nascentbiotech.com
Vero Beach, FL, April 7, 2016 – Nascent Biotech, Inc. (“Nascent Biotech, Inc.” or “the Company”) (OTC.NBIO), announced today the addition of Dr. Ralph Zipper, MD, FACOG, FPMRS to its Advisory Board. Dr. Zipper currently is a practicing physician and COO of Biofuse Medical Technologies, Inc.
“Dr. Zipper’s vast experience as an innovator in the specialty of Gynecology and an operator of various successful medical startup companies in Senior Management positions will help position Nascent Biotech for future development and corporate clinical direction,” said Nascent CEO, Sean Carrick
Mr. Carrick has known Dr. Zipper for approximately twenty years and encouraged Dr. Zipper to join Nascent Biotech’s already impressive group of medical professionals currently on its Advisory Board.
“I recognize the significance of Nascent’s primary asset, Pritumumab, to potentially benefit multiple cancers and am honored to be contributing to Nascent’s pathway to success,” said Dr. Zipper.
About Nascent Biotech, Inc.:
Nascent Biotech, Inc is a clinical-stage biotech company engaged in the development of monoclonal antibodies to be used in the treatment of various cancers. Its products are not commercially available. For further information please visit our website www.nascentbiotech.com.
Safe Harbor:
Statements in this press release about our future expectations constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc’s ability to target the medical professionals; Nascent Biotech Inc.’s ability to raise capital; as well as other risks. Additional information about these and other factors may be described in the Nascent Biotech Inc’s Form 10K, filed on May 2, 2015 and subsequent future filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
Contact Information:
Nascent Biotech, Inc.
Sean Carrick
President | CEO
601 21st Street Suite 300
Vero Beach, FL 32960
772.713.0541
sean.carrick@nascentbiotech.com
www.nascentbiotech.com